The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors.
 
Mengni Guo
No Relationships to Disclose
 
Jieying Liu
No Relationships to Disclose
 
Zohaib Ahmed
No Relationships to Disclose
 
James Yu
No Relationships to Disclose
 
Ruoyu Miao
No Relationships to Disclose
 
Jian Guan
No Relationships to Disclose
 
Mohammad Ali Esmaeil Pour
No Relationships to Disclose
 
Azadeh Khayyat
No Relationships to Disclose
 
Angela Grove
No Relationships to Disclose
 
Manoucher Manoucheri
No Relationships to Disclose
 
Mark A. Socinski
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Janssen; Lilly; Novartis
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst)
 
Tarek Mekhail
Honoraria - Amgen; AstraZeneca/Merck; Bristol-Myers Squibb; Genentech; Guardant Health; Lilly
Consulting or Advisory Role - AstraZeneca/Merck; Daiichi Sankyo
Speakers' Bureau - Amgen; AstraZeneca/Merck; Bristol-Myers Squibb; Genentech; Guardant Health; Lilly
Research Funding - Amgen; AstraZeneca/Merck; Bristol-Myers Squibb; Merck; Mirati Therapeutics; Pfizer